Upgrade to SI Premium - Free Trial

Immunomedics (IMMU) Names Dr. Robert Iannone Head of Research & Development and CMO

April 9, 2018 8:06 AM
Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leader in the field of antibody-drug conjugates (ADCs), today announced the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News Management Comments

Next Articles